Your browser doesn't support javascript.
loading
Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.
Yang, Yongli; Chai, Xiaojuan; Xin, Wenfang; Wang, Dongxu; Dai, Chaohui; Qian, Feng; Yang, Teddy.
Afiliação
  • Yang Y; Shanghai Public Health Clinical Center, Human Phenome Institute and School of Life Sciences, Fudan University, Shanghai, China.
  • Chai X; Shanghai ChemPartner Co., Ltd., China.
  • Xin W; Shanghai ChemPartner Co., Ltd., China.
  • Wang D; Shanghai ChemPartner Co., Ltd., China.
  • Dai C; Shanghai PharmaExplorer Co., Ltd., China.
  • Qian F; Shanghai PharmaExplorer Co., Ltd., China.
  • Yang T; Shanghai Public Health Clinical Center, Human Phenome Institute and School of Life Sciences, Fudan University, Shanghai, China.
FEBS Lett ; 595(11): 1587-1603, 2021 06.
Article em En | MEDLINE | ID: mdl-33792041
OX40 is a costimulatory molecule that belongs to the tumor necrosis factor receptor (TNFR) superfamily. OX40 agonist-based combinations are emerging as promising candidates for novel cancer immunotherapy. Clinical trials have shown that OX40 agonist antibodies could lead to better results in cancer patients. Using a hybridoma platform and three different types of immunization strategies, namely recombinant protein, DNA, and overexpressing cells, we identified a chimeric anti-OX40 antibody (mAb035-hIgG1 from DNA immunization) that shows excellent binding specificity, and slightly stronger activation of human memory CD4+ T cells and similar potent antitumor activity compared with BMS 986178, an anti-OX40 antibody currently being evaluated for the treatment of solid tumors. This paper further systematically investigates the antigen-specific immune response, the number of binders, epitope bins, and functional activities of antibodies among different immunization strategies. Interestingly, we found that different immunization strategies affect the biological activity of monoclonal antibodies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Linfócitos T CD4-Positivos / Imunização / Receptores OX40 / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Idioma: En Revista: FEBS Lett Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Linfócitos T CD4-Positivos / Imunização / Receptores OX40 / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Idioma: En Revista: FEBS Lett Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China